RUSNANO signs an investment agreement for the Blood Clotting Disorders Diagnostics project
RUSNANO and Sberbank Capital signed an investment agreement and the agreement on the rights of parties with Hematological Corporation (HemaCore), a project company to develop a new method of diagnosing disorders of blood coagulation.
The project was approved by the Supervisory Council of RUSNANO in September 2009. The HemaCore project company is established by Medical Innovations, a company founded by the authors of the project.
The project will be financed through a series of investment in HemoCore equity capital, totaling 545 million rubles, and a loan of 95 million rubles.
This project implies the creation of unique test devices that diagnose the blood clotting disorders. A single universal test is able to determine a slow blood coagulation (haemophilia) and excess levels of clotting, which leads to such diseases as thrombosis and thromboembolism (obstruction of the vessel by the detached clot). In developed countries thromboembolism is a major cause of heart attacks and strokes. The proposed efficient and inexpensive method of instant diagnostics solves the problem of determining the threat.
Mass production of diagnostic equipment and disposable test kits is to begin no later than September 2012.
"The most important competitive advantages of this project are the high level of diagnostic accuracy, reasonable pricing and user friendliness of devices. All of these will promote a unique technology of blood coagulation diagnosis", - says RUSNANO Managing Director Olga Shpichko.
Sberbank Capital is a 100% subsidiary of Sberbank of Russia involved in asset management. The main objective for Sberbank Capital is to increase the value and effectiveness of the consolidated portfolio of Sberbank of Russia.
Hematology Corporation (HemaCore) was founded in April 2010 with the aim to implement the project" Development of a new method of diagnosing disorders of blood coagulation. It is assumed that by 2015 the company will produce and sell at least 200 devices for the diagnosis of hemostasis and 1.5 million single-use consumable test kits annually with the sales volume of about 1.5 billion rubles. In the long run the company plans to rise the level of production to 8.9 million test kits per year. The company hopes to export 25% of the yield.
Medical Innovations was founded in September 2009 by a group of scientists. The company is the holder of intellectual property of the project.